Lipocine (LPCN) Projected to Announce Quarterly Earnings on Tuesday

Lipocine (NASDAQ:LPCN) will likely be announcing its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect the company to announce earnings of ($0.40) per share and revenue of $0.2130 million for the quarter. Investors can find conference call details on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Friday, August 7, 2026 at 9:30 AM ET.

Lipocine (NASDAQ:LPCN) last posted its earnings results on Thursday, May 7th. The specialty pharmaceutical company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.03). Lipocine had a negative net margin of 571.18% and a negative return on equity of 66.70%. The company had revenue of $0.12 million for the quarter, compared to analysts’ expectations of $0.16 million.

Lipocine Stock Up 2.6%

LPCN opened at $2.19 on Tuesday. The company has a market capitalization of $18.09 million, a PE ratio of -1.17 and a beta of 0.44. The firm has a 50-day simple moving average of $2.29 and a two-hundred day simple moving average of $5.10. Lipocine has a 52 week low of $1.81 and a 52 week high of $12.37.

Institutional Investors Weigh In On Lipocine

Hedge funds and other institutional investors have recently bought and sold shares of the company. Jane Street Group LLC purchased a new stake in Lipocine in the fourth quarter valued at about $85,000. Citadel Advisors LLC purchased a new stake in Lipocine in the third quarter valued at $41,000. Renaissance Technologies LLC boosted its stake in shares of Lipocine by 3.6% in the fourth quarter. Renaissance Technologies LLC now owns 37,397 shares of the specialty pharmaceutical company’s stock worth $300,000 after buying an additional 1,300 shares during the last quarter. Boothbay Fund Management LLC purchased a new stake in Lipocine in the 4th quarter worth approximately $441,000. Finally, Geode Capital Management LLC increased its holdings in Lipocine by 2.2% in the fourth quarter. Geode Capital Management LLC now owns 62,450 shares of the specialty pharmaceutical company’s stock valued at $502,000 after buying an additional 1,374 shares in the last quarter. Hedge funds and other institutional investors own 9.11% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. HC Wainwright reiterated a “neutral” rating on shares of Lipocine in a research report on Monday, April 6th. Weiss Ratings cut Lipocine from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, June 18th. Finally, Wall Street Zen raised shares of Lipocine from a “sell” rating to a “hold” rating in a research note on Saturday, July 18th. One analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $15.00.

Lipocine Company Profile

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.